Sarepta Therapeutics (NASDAQ:SRPT) Earns “Buy” Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report sent to investors on Thursday, Benzinga reports. The brokerage currently has a $166.00 price target on the biotechnology company’s stock.

SRPT has been the topic of a number of other research reports. Royal Bank of Canada lifted their price target on shares of Sarepta Therapeutics from $151.00 to $157.00 and gave the stock an outperform rating in a report on Thursday, February 29th. Barclays upped their price target on Sarepta Therapeutics from $141.00 to $185.00 and gave the company an overweight rating in a research report on Thursday, February 29th. Mizuho lifted their price objective on Sarepta Therapeutics from $130.00 to $145.00 and gave the stock a buy rating in a report on Wednesday, February 14th. Evercore ISI upped their price objective on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an in-line rating in a report on Tuesday, February 20th. Finally, BMO Capital Markets started coverage on shares of Sarepta Therapeutics in a research report on Wednesday, January 31st. They set an outperform rating and a $170.00 target price for the company. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of Moderate Buy and a consensus price target of $160.60.

Sarepta Therapeutics Stock Up 2.3 %

SRPT stock opened at $133.66 on Thursday. The stock has a market cap of $12.63 billion, a P/E ratio of 1,215.09 and a beta of 0.95. The company has a current ratio of 4.05, a quick ratio of 3.45 and a debt-to-equity ratio of 1.18. The stock’s fifty day simple moving average is $125.63 and its two-hundred day simple moving average is $110.76. Sarepta Therapeutics has a 1-year low of $55.25 and a 1-year high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The company had revenue of $413.50 million for the quarter, compared to the consensus estimate of $375.52 million. During the same period in the previous year, the firm earned ($1.44) EPS. The firm’s quarterly revenue was up 63.1% on a year-over-year basis. Analysts expect that Sarepta Therapeutics will post 2.23 EPS for the current year.

Insider Transactions at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 761 shares of Sarepta Therapeutics stock in a transaction on Monday, March 11th. The stock was sold at an average price of $122.93, for a total transaction of $93,549.73. Following the completion of the sale, the director now owns 7,516 shares of the company’s stock, valued at $923,941.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the transaction, the director now directly owns 7,516 shares in the company, valued at $923,941.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Ian Michael Estepan sold 1,200 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the sale, the chief financial officer now owns 39,114 shares of the company’s stock, valued at $5,018,326.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,096 shares of company stock valued at $2,739,419. 7.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. DMC Group LLC lifted its stake in Sarepta Therapeutics by 2.9% during the third quarter. DMC Group LLC now owns 3,297 shares of the biotechnology company’s stock worth $400,000 after purchasing an additional 93 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Sarepta Therapeutics by 5.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 95,865 shares of the biotechnology company’s stock worth $11,621,000 after buying an additional 4,763 shares during the last quarter. TD Asset Management Inc boosted its stake in Sarepta Therapeutics by 377.7% in the third quarter. TD Asset Management Inc now owns 204,626 shares of the biotechnology company’s stock worth $24,805,000 after buying an additional 161,788 shares in the last quarter. Eagle Health Investments LP grew its position in Sarepta Therapeutics by 79.0% during the third quarter. Eagle Health Investments LP now owns 174,212 shares of the biotechnology company’s stock valued at $21,118,000 after acquiring an additional 76,872 shares during the last quarter. Finally, Hudson Capital Management LLC purchased a new position in shares of Sarepta Therapeutics during the third quarter worth approximately $206,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.